This is a Phase 1, open-label, single center, dose escalation study to evaluate the safety
and pharmacokinetic profile of mAb AZD5396 and mAb AZD8076 following delivery of optimized
dMAb AZD5396 and dMAb AZD8076 with Hylenex® recombinant, administered by intramuscular
injection (IM) followed immediately by electroporation (EP) using the CELLECTRA® 2000 with
Side Port needle device, in a 2-dose regimen (Days 0 and 3) in healthy adults.
The hypothesis is that the administration of dMAb AZD5396 and dMAb AZD8076 will be safe and
associated with expression of mAb AZD5396 and mAb AZD8076 in serum.
Phase:
Phase 1
Details
Lead Sponsor:
Pablo Tebas
Collaborators:
AstraZeneca Inovio Pharmaceuticals The Wistar Institute United States Department of Defense